Opinion|Videos|August 1, 2024
Importance of Patient-Reported Outcomes
Author(s)Steven D. Nathan, MD
Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the potential impact of these novel treatments on disease progression, mortality, and patient-reported outcomes such as quality of life, survival time, and functional status?
- An important consideration in drug development is understanding the impact on patient-reported outcomes and quality of life. How are the clinical trials for idiopathic pulmonary fibrosis agents incorporating these measures?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
2
Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM
3
Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024
4
FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film
5
